HEALTH OF WOMAN. 2016.9(115):72–74; doi 10.15574/HW.2016.115.72

Features hormonal hemostasis in patients with benign hyper-plastic processes of breasts

Makarenko M., Govsieiev D., Gromova O., Martynova L., Tyan O.

A.A. Bogomolets National Medical University, Kiev

The objective: to study the incidence of gynecological diseases, clinical and hormonal parameters of the menstrual cycle in patients with benign hyper-plastic processes of breasts.

Patients and methods. 65 women with various forms of mastitis were investigated. The following investigations were conducted: mammologistic and gynecological investigation, mommologistic X-ray investigation, ultrasound of breasts and of the pelvic organs, endometrial aspiration biopsy that was followed by cytology; when it was necessary the diagnostic laparoscopy, colposcopy, hysteroscope with curettage and morphological investigation of the endometrium, hormone research and rectal temperature measurements were conducted.

Results. The frequency of the benign breast diseases was set: fibrocystic disease of breast – 32 women (49.2±6.20%), fibrous of breast – 16 women (24.6±5.34%), nodular of breasts – 8 women (12.3±4.07%), fibroadenoma – 6 women (9.2±3.59%), nodular disease of breasts on the background of fibroid changes – 3 women (4.6±2.60%). All in all, 96.9±2.14% of the patients had any gynecological diseases. Thus, the average age of the ‘debut’ of mastitis was 31.4±1.09 years; the hyper-plastic processes in the uterus was 35.2±1.17 years. Anovulation was detected in 17 (47.2±8.3%) patients, the lack of the luteal phase (NLF) was detected in 11 (30.6±7.6) patients.

Conclusions. Identified hormonal changes are typical for patients with the hyper-plastic processes of the reproductive organs with different localization (breasts, uterus, ovaries). Due to the commonality of the hormone changes in most cases mastitis is combined with the various gynecological diseases (96.9±2.14%).

Key words: gynecological pathology, hormonal changes, breast, factors of risk.

REFERENCES

1. Solopova AG, Safarov AA, Makatsaria AD. 2014. Experience mastopola application in the treatment of mastitis and premenstrual syndrome. Obstetrics, Gynecology and Reproduction. 4:38-41.

2. Zurochka AV, Tiunova TA. 2015. Current problems in the diagnosis of breast diseases in the large industrial city of Chelyabinsk region. Medical immunology 17(3):281-286.

3. Savas D. Soysal, Incken B. Kilic, Christian R Regenbrecht et al. 2015. Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer. Breast Cancer Research and Treatment. 151:709-715. https://doi.org/10.1007/s10549-015-3427-y; PMid:25981900

4. Marco Moschetta, Michele Telegrafo, Vincenzo Triggiani et al. 2015. Diabetic mastopathy: A diagnostic challenge in breast sonography. Journal of Clinical Ultrasound. 43:113-117. https://doi.org/10.1002/jcu.22246; PMid:25327165

5. Jonghyeon Kim, Eun-Kyung Kim, Min Jung Kim et al. 2016. Diabetic mastopathy: imaging features and the role of image-guided biopsy in its diagnosis. Ultrasonography 35(2):140-7. https://doi.org/10.14366/usg.15052; PMid:26810194 PMCid:PMC4825211

6. William E Byrd. 2006. Mastopathy as related to functional uterine bleedingю American Journal of Obstetrics and Gynecology. 72:1191-1196.

7. Hung WK, Ying M, Chan CM et al. 2009. Minimally invasive technology in the management of breast disease. Breast Cancer. 16:23-24. https://doi.org/10.1007/s12282-008-0072-x; PMid:18818988